Rivaroxaban Decreases Recurrent Venous Thromboembolisms In Patients With Deep Vein Thrombosis: A Meta-Analysis

Rivaroxaban (RIV), a new anticoagulant, has been widely used in the treatment of venous thromboembolisms. Deep vein thrombosis (DVT) is a common disease with a high mortality rate. This study focused on DVT patients to evaluate the risk of recurrent venous thromboembolisms (rVTE) and fatal bleeding after oral RIV treatment. Data were collected from randomized controlled trials (RCTs) of RIV versus conventional anticoagulants (CAs) in patients with DVT, through PUBMED, MEDLINE, and Cochrane CENTRAL. A total of 41,150 patients in 11 RCTS were included. Compared to CAs, RIV was associated with significant reduction of rVTE [odds ratio (OR) = 0.74; 95% confidence interval (CI) = 0.61-0.87] and fatal bleeding (OR = 0.377; 95% CI = 0.184-0.772). Simultaneously, there were no statistical differences regarding hemoglobin falling (>= 2 g/dl), transfusions (>= 2 units) (OR = 0.700; 95% CI = 0.398-1.230), total death (OR = 0.521; 95% CI = 0.244-1.112), and death from cardiovascular disease (OR = 0.685; 95% CI = 0.190-2.470). In conclusion, compared with CAs, oral RIV therapy in DVT patients gained more benefits in reducing riskd of rVTE, fatal bleeding, and so forth.